Cancer Immunotherapy Market Report 2026

Cancer Immunotherapy Market Overview

• Cancer Immunotherapy market size has reached to $124.09 billion in 2025 • Expected to grow to $210.39 billion in 2030 at a compound annual growth rate (CAGR) of 11.1% • Growth Driver: Driving Forces Cancer Incidence Surge And The Surge In Cancer Immunotherapy Demand • Market Trend: Breakthrough PD-1 Therapy Expands Access For Advanced Lung Cancer Patients • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Cancer Immunotherapy Market?

Cancer immunotherapy refers to a type of cancer therapy that strengthens your body's defenses against the disease. Your body's immune system aids in the defense against infections and other disorders. White blood cells, organs, and lymphatic system tissues make up this substance. Cancer immunotherapy comes in various forms, such as cytokines and vaccines, adoptive cell therapies, oncolytic viruses, tumor-infecting viruses, and others. The main types of products of cancer immunotherapy are monoclonal antibodies, checkpoint inhibitors, immunomodulators, vaccines, and cell therapy. Monoclonal antibodies are man-made proteins that function in the immune system such as human antibodies. Cancer immunotherapy is used to treat lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, and multiple myeloma. These are used in hospitals, cancer research centers, and clinics.

What Is The Cancer Immunotherapy Market Growth Forecast?

The cancer immunotherapy market size is expected to see rapid growth in the next few years. It will grow to $210.39 billion in 2030 at a compound annual growth rate (CAGR) of 11.1%. The growth in the forecast period can be attributed to growing adoption of CAR T-cell therapies, expansion into solid tumor indications, increasing investment in cancer vaccines, rising demand for targeted combination therapies, supportive reimbursement policies for immunotherapy. Major trends in the forecast period include rapid adoption of immune checkpoint inhibitors, growing use of combination immunotherapy regimens, expansion of cell-based cancer therapies, rising focus on personalized immunotherapy, increasing number of oncology clinical trials.

Global Cancer Immunotherapy Market Segmentation

1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy 2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma 3) By End User: Hospitals, Cancer Research Centers, Clinics Subsegments: 1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies 2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors 3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists 4) By Vaccines: Therapeutic Cancer Vaccines 5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy

What Is The Driver Of The Cancer Immunotherapy Market?

The rise in cancer incidence is expected to propel the cancer immunotherapy market. The factors contributing to the growth in cancer cases across the globe include tobacco, alcohol, obesity, a sedentary lifestyle, and environmental factors. This growth in cancer cases is expected to boost demand for cancer immunotherapies, as patients are increasingly investing in medical treatments with greater recovery and minimal pain. For instance, in July 2024, according to the projections published by Cancer Research UK, a UK-based cancer charity, cancer incidence rates in the United Kingdom are projected to increase for most types between 2023-2025 and 2038-2040, with rises ranging from less than 1% for breast cancer to 50% for eye cancer, while a smaller number of cancers are expected to see a decline, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Therefore, the increase in cancer incidence is expected to boost demand for cancer immunotherapy during forecast period.

Key Players In The Global Cancer Immunotherapy Market

Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.

Global Cancer Immunotherapy Market Trends and Insights

Major companies operating in the cancer immunotherapy market are focusing on developing innovative solutions such as PD-1 immunotherapies to expand access to advanced immune-based treatment options for patients with hard-to-treat cancers. A PD-1 immunotherapy is an immune checkpoint–targeting treatment designed to stimulate antitumor immune activity by blocking programmed death-1 pathway interactions. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical company specializing in oncology and biologics, launched HETRONIFLY (Serplulimab). The therapy is the first programmed death-1 inhibitor approved globally for extensive-stage small cell lung cancer and utilizes a dual mechanism targeting PD-L1 and PD-L2 with strong receptor internalization to enhance immune engagement. Its demonstrated survival benefit and substantially reduced cost compared with existing immunotherapies underscore its clinical value and broaden patient access to advanced cancer treatment in India.

What Are Latest Mergers And Acquisitions In The Cancer Immunotherapy Market?

In July 2024, Boehringer Ingelheim, a Germany-based pharmaceutical company, acquired Nerio Therapeutics for $1.3 billion. This acquisition will significantly enhance Boehringer Ingelheim's immuno-oncology portfolio by integrating Nerio's innovative preclinical program focused on immune checkpoint inhibitors. Nerio Therapeutics, a US-based biotech company, specializes in drug discovery and development, with a focus on phosphatases, a challenging yet highly promising class of therapeutic protein targets.

Regional Insights

North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Cancer Immunotherapy Market?

The cancer immunotherapy market includes revenues earned by entities by helping the immune system fight cancer. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Cancer Immunotherapy Market Report 2026?

The cancer immunotherapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the cancer immunotherapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.